Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI‐H/dMMR rectal cancer: A prospective, multicenter, phase Ib study

BACKGROUND: Neoadjuvant radiochemotherapy followed by radical surgery is the standard treatment strategy for local advanced rectal cancer (LARC). However, the efficacy of neoadjuvant radiochemotherapy is limited, especially for patients with DNA mismatch repair‐deficient (dMMR)/microsatellite instab...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaofen, Fang, Chao, Wang, Xin, Yu, Yongyang, Wang, Ziqiang, Qiu, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
REGISTERED REPORT STAGE 1
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741977/
https://www.ncbi.nlm.nih.gov/pubmed/35352512
http://dx.doi.org/10.1002/cam4.4720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741977/
https://www.ncbi.nlm.nih.gov/pubmed/35352512
http://dx.doi.org/10.1002/cam4.4720

Ejemplares similares